Eric Reish, MD
Ophthalmology · Alexandria, LANPI 1801086202
Payments from drug & device makers
Across 478 payments — averaging $329.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$123K
- Ivantis, Inc$13K
- Alcon$8K
- Alcon Research LLC$4K
- Rxsight Inc$3K
- Sight Sciences, Inc.$2K
- plus $5K from 25 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 107 | $122,553 |
| Ivantis, Inc | 26 | $13,108 |
| Alcon | 145 | $8,080 |
| Alcon Research LLC | 2 | $4,170 |
| Rxsight Inc | 19 | $2,717 |
| Sight Sciences, Inc. | 33 | $1,875 |
| NEW World Medical,inc. | 22 | $1,068 |
| AbbVie(2 entities) | 23 | $858 |
| Johnson & Johnson Surgical Vision, Inc. | 13 | $599 |
| Mallinckrodt Hospital Products Inc. | 11 | $391 |
| Biotissue Holdings Inc. | 6 | $353 |
| Aerie Pharmaceuticals, Inc. | 6 | $301 |
| Ocular Therapeutix, Inc. | 16 | $257 |
| Genentech USA, Inc. | 3 | $228 |
| Tarsus Pharmaceuticals, Inc. | 5 | $194 |
| Sun Pharmaceutical Industries Inc. | 6 | $134 |
| Rayner Intraocular Lenses Limited | 5 | $91 |
| Oyster Point Pharma, Inc. | 4 | $82 |
| Dompe US, Inc. | 4 | $81 |
| Merz Pharmaceuticals, LLC | 3 | $71 |
| Amgen(2 entities) | 4 | $70 |
| Apellis Pharmaceuticals, Inc. | 3 | $66 |
| Boston Scientific | 1 | $58 |
| Bausch & Lomb Americas Inc. | 3 | $52 |
| Biogen | 2 | $36 |
| Nova Eye, Inc. | 1 | $22 |
| Tearlab Corp | 1 | $18 |
| Harrow Eye, LLC | 1 | $15 |
| Novartis | 1 | $12 |
| Eyevance Pharmaceuticals LLC | 1 | $12 |
| Omeros Corporation | 1 | $11 |
How this compares
$157,581 in reported general payments places this provider in the 95th percentile of 286 ophthalmology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other ophthalmology in Alexandria
- Michael RedmondAlexandria$24K
- Patrick RedmondAlexandria$13K
- Thomas NortonAlexandria$8K
- Blake WilliamsonBaton Rouge$482K
- William ReadMonroe$303K
- Delmar CaldwellNew Orleans$282K
- Ruben GrigorianWest Monroe$192K
- Wyche ColemanShreveport$130K
- Ze ZhangNew Orleans$103K
- Rebecca MetzingerNew Orleans$63K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.